Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05985343 · ClinicalTrials.gov registry record · Phase 4
The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction
A Phase 4 study, sponsored by Clayton Petro.
- Completed
- Registry status
- Phase 4
- Development phase
- 184
- Enrollment target
NCT05985343 is a Phase 4 study that has completed, run by Clayton Petro. The registered enrollment target is 184 participants.
The verdict
NCT05985343, a Phase 4 study, has completed, sponsored by Clayton Petro.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 184 participants
- Enrollment target
Study Summary
The aim of the study is to determine if the usage of sugammadex would reduce the time to return of bowel function when compared to standard of care (neostigmine/glycopyrrolate) when used for neuromuscular blockade reversal in patients with open abdominal wall reconstruction (AWR).
Interventions
- DRUG Sugammadex
- DRUG Neostigmine / Glycopyrrolate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2024-01-15 |
| Est. Completion | 2025-06-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05985343
The ClinicalTrials.gov registry entry for NCT05985343 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clayton Petro, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sugammadex is the first listed.
NCT05985343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05985343 about?
NCT05985343 is a clinical study titled "The Impact of Sugammadex on Ileus After Abdominal Wall Reconstruction". The aim of the study is to determine if the usage of sugammadex would reduce the time to return of bowel function when compared to standard of care (neostigmine/glycopyrrolate) when used for neuromuscular blockade reversal in patients with open abdominal wall reconstruction (AWR).
What is the current status of trial NCT05985343?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 184 participants. The study started on 2024-01-15. Estimated completion is 2025-06-02.
What interventions are being tested in trial NCT05985343?
The interventions under investigation include: Sugammadex (DRUG), Neostigmine / Glycopyrrolate (DRUG).
Who is sponsoring clinical trial NCT05985343?
This trial is sponsored by Clayton Petro, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.